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Abstract
Antiphospholipid antibodies (aPL) generated in experimental animals cross-react with ATP. We therefore examined the
possibility that aPL IgG from human subjects bind to ATP by afﬁnity column and an enzyme linked immunosorbent assay
(ELISA). Sera with high levels of aPL IgG were collected from 12 patients with the antiphospholipid syndrome (APS). IgG
fractions from 10 of 12 APS patients contained aPL that could be afﬁnity-bound to an ATP column and completely eluted
with NaCl 0.5M. A signiﬁcant (.50%) inhibition of aPL IgG binding by ATP 5mM was found in the majority. Similar
inhibition was obtained with ADP but not with AMP or cAMP. All the afﬁnity puriﬁed anti-ATP antibodies also bound b2-
glycoprotein-I (b2-GPI, also known as apolipoprotein H) suggesting that, similar to most pathogenic aPL, their binding
depends on this serum cofactor. We further investigated this possibility and found that the binding of b2-GPI to the ATP
column was similar to that of aPL IgG in that most was reversed by NaCl 0.5M. Furthermore, addition of b2-GPI to aPL IgG
signiﬁcantly increased the amount of aPL binding to an ATP column. We conclude that aPL IgG bind ATP, probably through
b2-GPI. This binding could interfere with the normal extracellular function of ATP and similar neurotransmitters.
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Introduction
Antiphospholipid antibodies (aPL) are deﬁned as
immunoglobulins which bind anionic phospholipids.
The occurrence of such antibodies, especially IgG aPL,
in patients with clinical manifestations such as
thromboembolic disease and recurrent abortions,
deﬁnes the antiphospholipid syndrome (APS, or
Hughes’ syndrome) (Hughes 1985, Asherson et al.
1996).Acentralissueinthestudyoftheseantibodieshas
beentheirantigenicspeciﬁcity.Theantibodiesbywhich
this syndrome was named were initially measured by
binding to cardiolipin (Harris et al. 1983). Sub-
sequently, it was found that they cross-react with other
phospholipidssuchasphosphatidylserine(Gilburdetal.
1993) as well as with DNA (Asherson and Shoenfeld
1994) which is rich in phosphate groups. Some aPL
bind endothelial cells (Del Papa et al. 1995, Dueymes
et al. 1996, Bordron et al. 1998). A crucial observation
has been that aPL, including monoclonal antibodies,




of aPL to phospholipids and related antigens such as
endothelial cells.
In addition to phospholipids, aPL bind other
antigens such as adenosine triphosphate (ATP). This
phenomenon has been described with monoclonal
and polyclonal aPL induced in experimental animals
which have been shown to bind to ATP utilizing a
lyposome based assay (Wassef et al. 1984, Alving et al.
1987, Wassef et al. 1993). These reports are of special
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biochemical reactions as well as its well-established
role as a neurotransmitter (Vizi et al. 1997). However,
since the aPL reacting with ATP were derived
experimentally in animals their relevance to human
disease is unknown. We now present evidence that
aPL IgG from human APS patients also bind ATPand
that such binding may involve the serum cofactor
b2GPI.
Methods
All subjects had high serum levels of aPL IgG (.20
GPLU) by a standard assay based on the method of
Harris (Harris 1990) and had at least thrombosis or
recurrent abortions as well as neurological manifes-
tations. Subjects included 12 patients with APS aged
32–72 years who did not fulﬁll the American
Rheumatism Association criteria for systemic lupus
erythematosus (SLE). All patients were treated with
aspirin, 6 were treated with oral anticoagulants and
none received immunosupressive drugs. In view of
the potential relevance of ATP binding antibodies to
the brain we included patients with involvement of the
central nervous system such as dementia or stroke.
Dementia was diagnosed by DSM-IV (Association AP
1994) criteria and supported by cognitive examin-
ations in seven of the APS patients. The remaining
subjects without dementia had strokes. Controls were
age matched without immunological or neurological
disease (n ¼ 10). All samples were obtained by
informed consent as approved by the Tel Aviv
University ethics committee.
The ELISA method used for the measurement of
aPL was similar to that previously described (Harris
1990) except for some modiﬁcations: Phospholipids
were obtained from Sigma (St Louis, MO). Coating of
antigen (100mg/ml) in ethanol (for cardiolipin (CL))
or chloroform/methanol 1:5 (v:v, for phosphatidic
acid (PA), phosphatidylinositol (PI), phosphatidylser-
ine (PS), phosphatidylcholine (PC) and phosphatidy-
lethanolamine (PE)) was performed by allowing
samples to evaporate overnight at 48C in Linbro-
Flow (ICN Biomedicals, CA) polystyrene ELISA
plates. In the ELISA for anti-b2GPI antibodies, the
plates were coated with b2GPI (prepared by the
method of Polz et al. (1980), 1mg/well) diluted in
phosphate buffered saline (PBS) overnight at 48C.
Non-speciﬁc binding to the plates was blocked with
1% bovine serum albumin (BSA) in PBS for 2h. The
plates were then washed ( £ 10) with water, and
patients sera were incubated overnight in PBS with
5% fetal calf serum (FCS, as a source of b2GPI). In
some tests, FCS was omitted in order to test the serum
dependence of the antibody binding. In competition
assays, the competing substance was added to the
diluted serum sample 10min prior to incubation in
the plate. After washing the plates, bound human IgG
was measured by means of an alkaline phosphatase
conjugated second antibody (Sigma, St Louis, MO)
using p-nitrophenyl phosphate as a substrate, and
absorbance was read at 405nm in each well after
30min. All samples were tested in duplicate or
triplicate on antibody coated wells and on wells
coated with ethanol or chloroform/methanol or PBS.
For each sample, speciﬁc binding was calculated by
subtracting the values obtained in the wells without
antigen from those obtained in antigen-coated wells.
Puriﬁcation of IgG was essential in order to ensure
that serum-derived ATPase activity did not destroy
the ligand in the ATP afﬁnity column experiments.
The puriﬁcation was performed by standard pro-
cedures on Protein-G columns (Zymed). In brief,
ﬁltered serum was applied to the column diluted 1:3 in
Na2HPO4 0.02M, NaCl 0.15M, pH 7.0 (sodium
phosphate buffer). The column was then washed (10
volumes) with sodium phosphate buffer. IgG, bound
to the column, was eluted with 0.1M Acetic acid, pH
2.8, and the pH of collected fractions was immediately
neutralized with Tris HCl 1M, pH 8.0. Puriﬁed IgG
was quantiﬁed by measuring absorbance at 280nm
and its aPL content was assayed by ELISA as
described above.
Afﬁnity puriﬁcation of ATP-binding IgG was
performed on a 1ml ATP-agarose column (activation
by cyanogen bromide, attachment of 2–10mmoles
ATP at C-8, Sigma A2767). Puriﬁed IgG fractions
were passed three times through the column (10mM
Tris, pH ¼ 8.0). Elution was performed with 10ml
each of 100, 200, 300, 400 and 500mM NaCl.
In some samples, further elution was attempted by
10ml each of 100mM acetate pH ¼ 2.8 and 100mM
triethylamine, pH ¼ 11.5. The pH of the fractions was
immediately neutralized with 1M Tris pH ¼ 8.0 and
the absorbance at 280nm was determined. Relevant
fractions were then assayed by ELISA for aPL IgG.
When not in use the columns were stored in PBS with
0.1% sodium azide.
Results
Binding of antibodies to ATP was demonstrated by
afﬁnity puriﬁcation on ATP columns. Puriﬁcation of
anti-ATPantibodies from the sera of two APS patients
(aged 68 and 72) with dementia are presented in
Figures 1 and 2. In each patient, fractions collected
from the column were assayed for IgG content by
spectroscopy (280nm) and by anti-cardiolipin (aCL)
ELISA as a measure of aPL IgG content. As can be
seen, in the two patients (Figures 1 and 2) a signiﬁcant
amount of IgG bound to the column and was eluted
with 500mM NaCl. No additional IgG was eluted at
pH 2.8 or 11.5 (Figure 2). In these two patients, all
aPL IgG were contained in the IgG eluted from the
column while the IgG which was not bound by the
column did not contain aPL IgG. In 10 of the 12
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afﬁnity bound by the ATP column. In the two
remaining APS patients, one with dementia and one
with stroke, less than 40% of aPL bound to ATP.
There were no signiﬁcant differences between the
demented and non-demented patients. Control IgG
with no aPL did not bind to ATP to any measurable
degree.
All competition assays were performed with either
PA or CL as antigens and since similar results were
obtained with both these antigens, those with PA are
presented in Figures 3 and 4. Figure 3 presents the
binding to PA of antibodies from the serum (dilutions
1:400 and 1:800) of a 60-year-old APS patient (with a
history of recurrent abortions and dementia) in the
presence of 0–10mM of ATP. As can be seen, at 4–
6mM ATP a signiﬁcant inhibition of binding to PA
was observed at both serum dilutions. In order to
examine whether other phosphorylated purines may
also inhibit binding of this serum (dilution 1:800) we
utilized 5mM concentrations of ATP, adenosine
diphosphate (ADP), adenosine monophosphate
(AMP) and cyclic-AMP (cAMP). Results from such
an inhibition ELISA are presented in Figure 4 which
demonstrates the greatest inhibition with ATP and
ADP, less with AMP and none with cAMP. Similar
results were obtained with IgG from 4 additional APS
Figure 1. Results of afﬁnity puriﬁcation of anti-ATP IgG from a
demented APS patient performed as described in the text. Elution
buffers are indicated. Fractions collected from the column were
assayed for totalIgGcontentbyspectroscopy(280nm, upper panel)
and for anticardiolipin antibodies (aCL) by ELISA (lower panel).
The results indicate that most aCL could be eluted by high salt
(500mM NaCl).
Figure 2. Results of afﬁnity puriﬁcation of anti-ATP IgG from a
demented APS patient performed as described in the text. Elution
buffers are indicated. Fractions collected from the column were
assayed for total IgGcontentby spectroscopy (280nm, upper panel)
and for anticardiolipin IgG (aCL) by ELISA (lower panel). The
results indicate that most aCL could be eluted by the high salt
(500mM NaCl) concentration and that no additional antibody was
eluted by pH changes.
Figure 3. The binding to PA of antibodies from the serum
(dilutions 1:400 and 1:800) of an APS patient in the presence of 0–
10mM of ATP. The results indicate that signiﬁcant inhibition of
antibody binding was achieved at concentrations exceeding 4mM
ATP.
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column, aPL binding (measured to CL) could also be
inhibited signiﬁcantly by 5mM ATP in IgG (61 ^ 4%
inhibition, mean ^SE). In contrast, aPL IgG that was
not bound by the ATP column was signiﬁcantly less
inhibited by 5mM ATP (25 ^ 12% inhibition,
p , 0.01, paired t-test).
Since binding of aPL generally depends on the
presence of the serum protein b2GPI, the serum
dependency of the ATP-afﬁnity puriﬁed aPL was
examined in samples from 8 patients. All aPL, either
bound or not bound by the ATP column, were
completely dependent on the presence of serum for
binding to cardiolipin (less than 2% of the signal in the
absence of FCS). Further examination of IgG from
the same 8 patient samples eluted from the ATP
column revealed that they bound similarly to
negatively charged phospholipids such as CL, PS, PI
and PA but not to the neutral phospholipids PC and
PE (Figure 5). High levels of binding to the protein
cofactor b2GPI were measured in all the samples
(Figure 5) providing direct evidence for the inter-
action of ATP-binding aPL and this protein.
The serum dependence and b2GPI binding proper-
ties of the ATP binding IgG raised the possibility that
IgG binding to the ATP column may involve
complexes of IgG with b2GPI. This possibility was
examined by a series of experiments in which the
binding of b2GPI to ATP was measured. As can be
seen in a representative experiment (Figure 6), about
half of the b2GPI applied bound to the ATP column
and could be eluted by 500mM NaCl. In additional
experiments we found that 300mM NaCl was
sufﬁcient to elute all b2GPI from the ATP column
(not shown). Figure 6 also presents the amount of IgG
from one patient bound by the ATP column. As can
bee seen, there was a 4 fold increase in the amount of
Figure 4. The binding of IgG to PA, measured in the serum of an
APS patient (diluted 1:400 in phosphate buffered saline, PBS) and
in the presence of 5mM concentrations of ATP, ADP, AMP and
cAMP. The results are the means ^ SE of experiments performed in
triplicate with one representative serum (of 5 tested).
Figure 5. The antigenic speciﬁcity of IgG that was bound by an
ATP column. Binding of IgG to CL, PI, PA, PS, PC, PE and b2-
Glycoprotein I (b2GPI) were measured in samples obtained from 8
patients as described in the methods. Results are presented as
mean ^ SE.
 
Figure 6. The inﬂuence of b2GPI on the binding of IgG to an ATP
column. IgG (1.5mg) from a demented APS patient with high levels
of aCL and b2GPI (0.5mg) were applied separately or in
combination to an ATP column. Fractions that ﬂowed through
the column (FT) or were bound by the column (bound) were
collected and assayed for protein as described in the Methods. All
protein could be eluted from the column with 500mM NaCl.
J. Chapman et al. 178protein bound by the ATP column when the IgG was
applied to the ATP column together with b2GPI. The
increased amount of protein bound to the column
could only partially be accounted for by b2GPI and
therefore represents a 2–3 fold increase in the amount
of IgG bound to the column.
Discussion
The main ﬁnding in the present study was that aPL
IgG from many APS patients also bind ATP. This was
established by both direct binding and competition
assays. Though the competition assay results may
indicate speciﬁc cross-reactivity with ATP, they may
also be non-speciﬁc. The co-puriﬁcation of anti-ATP
and aPL IgG by afﬁnity chromatography in most
patients indicates a speciﬁc IgG-ATP interaction and
this interpretation is strengthened by the identiﬁcation
in several patients of aPL–IgG which do not bind
ATP. The anti-ATP IgG were very common in the
group of APS patients examined and there was no
indication that they were speciﬁcally associated with
dementia or with advanced age. A more detailed
examination of the clinical correlates of these
antibodies will necessitate signiﬁcantly larger groups
of patients with different manifestations of APS as well
as relevant controls.
In this study, as well as in previous studies in rats
(Wassef et al. 1984, Wassef et al. 1993), aPL IgG
binding could be inhibited by a range of phos-
phorylated compounds. Other workers have shown
cross-reactivity of aPL antibodies with DNA (Eilat
et al. 1986, Smeenk et al. 1987). Furthermore, the
“true” antigen bound by aPL–IgG is now under
intense debate (Galli 1996, Roubey 1996),
especially regarding the role of b2GPI which is
essential for the binding of aPL–IgG in the
standard ELISA assay (Galli et al. 1990). In our
experiments, none of the afﬁnity puriﬁed anti-ATP
IgG bound zwitterionic phospholipids such as PC
or PE and their binding to CL was totally
dependent on the presence of serum. These
ﬁndings raised the possibility that aPL were afﬁnity
bound to ATP through a protein cofactor such as
b2GPI, and this hypothesis is supported by the
signiﬁcant binding of b2GPI to the ATP column
which could be completely reversed by the same
concentrations of NaCl used to elute anti-ATP
antibodies. Adding b2GPI to an IgG sample
increased the amount of IgG bound to the ATP
column (Figure 6), although it is not clear whether
this is the results of enhanced binding of IgG,
b2GPI, or both, to the column. A plausible
explanation for the binding of aPL to the ATP
column is through the presence of b2GPI or other
proteins in the puriﬁed IgG preparations. Though
these preparations are highly enriched in IgG, any
proteins complexed with these antibodies are co-
puriﬁed in the procedure. The presence of b2GPI
has been recorded in immune complexes from
patients with SLE (George et al. 1999) and in
preliminary studies we have found a band corre-
sponding to b2GPI in protein G puriﬁed IgG from
APS patients. Further studies are needed to
substantiate this hypothesis.
aPL IgG cross-react with many antigens, but their
pathogenic potential depends on several factors
including their concentration and the availability of
relevant antigens. Such considerations may pertain to
the potential functional signiﬁcance of the present
results: At the respective levels of intracellular ATP
(5mM) and IgG (less than 1/100 serum concen-
tration) ATP may inhibit aPL IgG binding as found in
vitro in the present study. It is tempting to suggest that
the intracellular concentration of ATP in lymphocytes
enables them to secrete aPL IgG in spite of the ability
of these antibodies to bind cell phospholipids. In
contrast, in the extracellular space the concentration
of ATP is in the mM range and the higher
concentrations of ATP-binding IgG in some patients
may limit ATP from functioning as a neurotransmitter
binding to purinergic receptors (Vizi et al. 1997).
Thus these antibodies, by binding to ATP or other
purinergic transmitters such as ADP, may modulate
their effect.
High levels of circulating aPL IgG have been
implicated in neurological diseases such as focal
cerebral ischemia, myelopathy, Guillain–Barre syn-
drome, migraine, chorea, epilepsy and dementia
(Lubbe and Walker 1983, Coull et al. 1987, Levine
et al. 1987, Inzelberg and Korczyn 1989, Inzelberg
et al. 1992, Herranz et al. 1994, Levine et al. 1995,
Cervera et al. 1997). The pathogenesis of nervous
system disease associated with aPL IgG is still
under investigation. Much of the effort has been
aimed at evaluating these antibodies as a risk factor
for stroke (Coull et al. 1987, Levine et al. 1995).
However, the ubiquitous distribution of phospholi-
pids provides a theoretical basis both for vascular
lesions and for direct damage to the brain. aPL IgG
h a v eb e e ns h o w nt ob i n dt ob r a i nv a s c u l a r
endothelium, platelet membranes, neuronal mem-
branes and myelin sheaths, and may consequently
alter neural structure and function directly or
indirectly (Del Papa et al. 1995, Fanelli et al.
1997). Permeabilization of synaptic structures by
direct binding of aPL has recently been proposed as
a pathogenetic mechanism in APS (Chapman et al.
1999). This may be relevant since several neuro-
logical manifestations cannot be explained as
consequences of vascular damage. A further
possibility worth consideration is that aPL anti-
bodies bind neurotransmitters. The results of the
present study may provide the basis for establishing
such pathogenetic mechanisms in APS involving the
nervous system.
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